Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.
Tisento Therapeutics has raised $81.0M in total funding. The most recent round was Series A. The last funding was announced in July 2023.
Tisento Therapeutics's investors include Venrock, Polaris Partners, Invus, Sanofi Ventures, Cyclerion Therapeutics.
Tisento Therapeutics is headquartered in Cambridge, United States.
Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.
Tisento Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tisento Therapeutics — Funding & Investors." VCBacked, July 31, 2023, https://www.vcbacked.co/company/tisento-therapeutics. Accessed September 14, 2026.
VCBacked. (2023). Tisento Therapeutics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/tisento-therapeutics
{{cite web |title=Tisento Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tisento-therapeutics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated